ME vs. SKIN, VLTA, OPFI, EMBK, HLLY, INVA, BCYC, VRNA, LQDA, and OPK
Should you be buying 23andMe stock or one of its competitors? The main competitors of 23andMe include Beauty Health (SKIN), Volta (VLTA), OppFi (OPFI), Embark Technology (EMBK), Holley (HLLY), Innoviva (INVA), Bicycle Therapeutics (BCYC), Verona Pharma (VRNA), Liquidia (LQDA), and OPKO Health (OPK).
23andMe (NASDAQ:ME) and Beauty Health (NASDAQ:SKIN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.
In the previous week, Beauty Health had 16 more articles in the media than 23andMe. MarketBeat recorded 21 mentions for Beauty Health and 5 mentions for 23andMe. Beauty Health's average media sentiment score of 0.87 beat 23andMe's score of -0.05 indicating that Beauty Health is being referred to more favorably in the news media.
23andMe has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, Beauty Health has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.
23andMe presently has a consensus target price of $0.47, suggesting a potential downside of 13.79%. Beauty Health has a consensus target price of $6.29, suggesting a potential upside of 184.42%. Given Beauty Health's higher probable upside, analysts plainly believe Beauty Health is more favorable than 23andMe.
Beauty Health received 28 more outperform votes than 23andMe when rated by MarketBeat users. However, 63.16% of users gave 23andMe an outperform vote while only 48.78% of users gave Beauty Health an outperform vote.
Beauty Health has a net margin of -20.48% compared to 23andMe's net margin of -303.55%. Beauty Health's return on equity of -0.02% beat 23andMe's return on equity.
Beauty Health has higher revenue and earnings than 23andMe. Beauty Health is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks.
36.1% of 23andMe shares are owned by institutional investors. Comparatively, 93.3% of Beauty Health shares are owned by institutional investors. 27.6% of 23andMe shares are owned by company insiders. Comparatively, 41.0% of Beauty Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Beauty Health beats 23andMe on 13 of the 18 factors compared between the two stocks.
Get 23andMe News Delivered to You Automatically
Sign up to receive the latest news and ratings for ME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
